Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
NALDEBAIN ER injection, invented by Taiwanese, launched in 2017, is a nalbuphine synthetic prodrug with oil-based solution to extend the release in human body by intramuscular injection. It was approved for the premedication use for moderate to severe pain relief, expected after surgery. There was limited experience with the combination of medication and different type of surgeries. Only the effect of operative analgesia on the hemorrhoidectomy patients have been well studied. Through reviewing the past medical cases, the pain intensity after receiving take down of anastomosis was about 4 to 7 points (moderate pain), lasing about 1 to 3 days. It was a suitable population with multi-day analgesic unmet need.
At present, the standard treatment after take down of anastomosis in the CMUH was morphine as needed. This treatment might not provide for well-controlled postoperative pain management. Patients might receive more painkillers when they needed than before pain occurred. Plus, it also cost more postoperative medical care. Therefore, this study intended to compare the standard treatment and NALDEBAIN for postoperative outcomes, safety and satisfaction.
The study will enroll patients scheduled to electively undergo take down of anastomosis. Eligible subjects were randomly divided into two groups, one receiving NALDEBAIN and the other receiving standard treatment. The study will evaluate pain intensity, dosage of supplement analgesics, incidence of adverse reactions, patient satisfaction, time of the first fart after surgery, and duration of postoperative hospital stay.
This is an open-labeled, randomized clinical trial. After ICFs are signed, patients' medical history will be gained for checking if they are eligible for this study or not. And then, on Day -1, eligible ones will randomly be divide into two separate group: NALDEBAIN or MORPHINE. Group NALDEBAIN will receive Nadebain by gluteus maximus injection between 12 and 24 hours prior to surgery for postoperative pain relief. Group MORPHINE will receive morphine as needed after surgery. All necessary data will be gain form EMR or patient dairies.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NALDEBAIN | Experimental | In group NALDEBAIN, subjects will receive single dose of Naldebain (150 mg/2 ml) by gluteus maximus injection between 12 and 24 hours prior to surgery. |
|
| MORPHINE | Active Comparator | In group MORPHINE, subjects will receive morphine as needed after surgery. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Naldebain | Drug | In Naldebain group, patients will be injected with Naldebain (150 mg/2 ml, IM injection) between 12 and 24 hours prior to surgery. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Supplemental analgesics | The consumption of total amount (mg) of supplemental analgesics administered after surgery. | From Day 0 to Day 7 |
| Measure | Description | Time Frame |
|---|---|---|
| Pain assessment: VAS | Using visual analog scale (VAS) with grades from 0 (no pain) to 10 (worst pain) | 2 hours after surgery |
| Pain assessment: VAS | Using visual analog scale (VAS) with grades from 0 (no pain) to 10 (worst pain) |
| Measure | Description | Time Frame |
|---|---|---|
| Time of first farting | Observing when patients are able to pass gas after surgery | From post-OP to Day 7 |
| Date of discharge | Observing when the condition of patients is good enough to discharge |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hung-Chang Chen | Contact | 04-22052121 | 81-221071 | D96591@mail.cmuh.org.tw |
| Name | Affiliation | Role |
|---|---|---|
| Hung-Chang Chen, MD | China Medical University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| China Medical University & Hospital | Recruiting | Taichung | 404 | Taiwan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010149 | Pain, Postoperative |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Morpine | Drug | In Morphine group, patients will receive morphine as needed after surgery. |
|
| 6 hours after surgery |
| Pain assessment: VAS | Using visual analog scale (VAS) with grades from 0 (no pain) to 10 (worst pain) | 24 hours after surgery |
| Pain assessment: VAS | Using visual analog scale (VAS) with grades from 0 (no pain) to 10 (worst pain), once daily | From Day 2 to Day 7 |
| Pain assessment: area under the curve of VAS | Pain assessment (time-specific pain intensity) calculated as the area under the curve of VAS pain intensity scores through 7 days after surgery | From post-OP to Day 7 |
| Patient satisfaction: frequency of each option | Calculating the frequency of each option: highly satisfied, satisfied, uncertain, dissatisfied and very dissatisfied | Day 7 |
| frequency of adverse event | Recording the frequency of treatment-emergent adverse event (TEAE) | From Day-1 to Day 7 |
| From post-OP to Day 7 |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |